Annual Total Expenses
$5.56 B
+$996.40 M+21.83%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual total expenses is currently $5.56 billion, with the most recent change of +$996.40 million (+21.83%) on 31 December 2023. During the last 3 years, it has risen by +$2.23 billion (+66.70%). VRTX annual total expenses is now at all-time high.VRTX Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Expenses
$1.64 B
-$70.40 M-4.12%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly total expenses is currently $1.64 billion, with the most recent change of -$70.40 million (-4.12%) on 30 September 2024. Over the past year, it has increased by +$247.80 million (+17.80%). VRTX quarterly total expenses is now -4.12% below its all-time high of $1.71 billion, reached on 30 June 2024.VRTX Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX Total Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +21.8% | +17.8% |
| 3 y3 years | +66.7% | +81.9% |
| 5 y5 years | +133.3% | +93.5% |
VRTX Total Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +66.7% | -4.1% | +81.9% |
| 5 y | 5 years | at high | +133.3% | -4.1% | +106.8% |
| alltime | all time | at high | >+9999.0% | -4.1% | >+9999.0% |
Vertex Pharmaceuticals Incorporated Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.64 B(-4.1%) |
| June 2024 | - | $1.71 B(+16.0%) |
| Mar 2024 | - | $1.47 B(-5.6%) |
| Dec 2023 | $5.56 B(+21.8%) | $1.56 B(+12.2%) |
| Sept 2023 | - | $1.39 B(+2.6%) |
| June 2023 | - | $1.36 B(+8.5%) |
| Mar 2023 | - | $1.25 B(+0.5%) |
| Dec 2022 | $4.57 B(+24.0%) | $1.24 B(+5.4%) |
| Sept 2022 | - | $1.18 B(+9.7%) |
| June 2022 | - | $1.08 B(+1.4%) |
| Mar 2022 | - | $1.06 B(-0.8%) |
| Dec 2021 | $3.68 B(+10.4%) | $1.07 B(+18.7%) |
| Sept 2021 | - | $901.70 M(+3.5%) |
| June 2021 | - | $871.30 M(+3.7%) |
| Mar 2021 | - | $840.40 M(-4.7%) |
| Dec 2020 | $3.34 B(+12.7%) | $881.53 M(+2.0%) |
| Sept 2020 | - | $864.23 M(+8.4%) |
| June 2020 | - | $797.25 M(+0.5%) |
| Mar 2020 | - | $793.28 M(-7.8%) |
| Dec 2019 | $2.96 B(+24.2%) | $860.30 M(+1.5%) |
| Sept 2019 | - | $847.54 M(+26.2%) |
| June 2019 | - | $671.33 M(+15.4%) |
| Mar 2019 | - | $581.63 M(-18.5%) |
| Dec 2018 | $2.38 B(+13.7%) | $713.38 M(+23.2%) |
| Sept 2018 | - | $579.06 M(-0.0%) |
| June 2018 | - | $579.22 M(+13.1%) |
| Mar 2018 | - | $511.97 M(-2.6%) |
| Dec 2017 | $2.10 B(+23.9%) | $525.51 M(-19.0%) |
| Sept 2017 | - | $648.53 M(+32.9%) |
| June 2017 | - | $487.90 M(+12.5%) |
| Mar 2017 | - | $433.88 M(+3.6%) |
| Dec 2016 | $1.69 B(+13.0%) | $418.84 M(-3.2%) |
| Sept 2016 | - | $432.50 M(+1.1%) |
| June 2016 | - | $427.91 M(+3.9%) |
| Mar 2016 | - | $411.72 M(-12.4%) |
| Dec 2015 | $1.50 B(+22.5%) | $470.12 M(+24.4%) |
| Sept 2015 | - | $378.02 M(+12.8%) |
| June 2015 | - | $335.11 M(+6.8%) |
| Mar 2015 | - | $313.77 M(+6.7%) |
| Dec 2014 | $1.22 B(-10.7%) | $294.02 M(+4.9%) |
| Sept 2014 | - | $280.35 M(-12.2%) |
| June 2014 | - | $319.23 M(-2.8%) |
| Mar 2014 | - | $328.31 M(-1.6%) |
| Dec 2013 | $1.37 B(-7.4%) | $333.78 M(+0.2%) |
| Sept 2013 | - | $333.21 M(-9.2%) |
| June 2013 | - | $366.91 M(+3.7%) |
| Mar 2013 | - | $353.72 M(-3.6%) |
| Dec 2012 | $1.48 B(+24.4%) | $366.88 M(+9.1%) |
| Sept 2012 | - | $336.38 M(-21.5%) |
| June 2012 | - | $428.48 M(+23.6%) |
| Mar 2012 | - | $346.73 M(+2.4%) |
| Dec 2011 | $1.19 B(+41.9%) | $338.45 M(+0.1%) |
| Sept 2011 | - | $338.11 M(+20.9%) |
| June 2011 | - | $279.57 M(+20.1%) |
| Mar 2011 | - | $232.80 M(-0.7%) |
| Dec 2010 | $837.95 M(+20.6%) | $234.41 M(+5.3%) |
| Sept 2010 | - | $222.52 M(+11.8%) |
| June 2010 | - | $199.08 M(+9.4%) |
| Mar 2010 | - | $181.93 M(+6.1%) |
| Dec 2009 | $694.67 M(+9.6%) | $171.45 M(-0.6%) |
| Sept 2009 | - | $172.42 M(-1.5%) |
| June 2009 | - | $175.12 M(-0.3%) |
| Mar 2009 | - | $175.68 M(+1.5%) |
| Dec 2008 | $633.89 M(+3.6%) | $173.03 M(+7.2%) |
| Sept 2008 | - | $161.35 M(+1.0%) |
| June 2008 | - | $159.72 M(+14.3%) |
| Mar 2008 | - | $139.78 M(-1.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $611.68 M(+38.5%) | $142.46 M(-7.4%) |
| Sept 2007 | - | $153.93 M(-5.5%) |
| June 2007 | - | $162.91 M(+6.9%) |
| Mar 2007 | - | $152.38 M(+18.9%) |
| Dec 2006 | $441.74 M(+46.0%) | $128.16 M(+12.4%) |
| Sept 2006 | - | $114.00 M(+5.1%) |
| June 2006 | - | $108.50 M(+19.1%) |
| Mar 2006 | - | $91.08 M(+8.7%) |
| Dec 2005 | $302.63 M(+26.1%) | $83.75 M(+8.6%) |
| Sept 2005 | - | $77.12 M(+6.1%) |
| June 2005 | - | $72.66 M(+5.2%) |
| Mar 2005 | - | $69.09 M(+1.7%) |
| Dec 2004 | $239.95 M(-0.8%) | $67.91 M(+11.6%) |
| Sept 2004 | - | $60.86 M(+3.3%) |
| June 2004 | - | $58.94 M(+12.8%) |
| Mar 2004 | - | $52.24 M(-12.6%) |
| Dec 2003 | $241.84 M(-0.4%) | $59.78 M(-0.1%) |
| Sept 2003 | - | $59.86 M(-43.8%) |
| June 2003 | - | $106.58 M(+3032.0%) |
| Mar 2003 | - | $3.40 M(-91.4%) |
| Dec 2002 | $242.73 M(+21.1%) | $39.49 M(-43.7%) |
| Sept 2002 | - | $70.13 M(+5.7%) |
| June 2002 | - | $66.36 M(-0.6%) |
| Mar 2002 | - | $66.76 M(+126.7%) |
| Dec 2001 | $200.40 M(+5.1%) | $29.45 M(-51.5%) |
| Sept 2001 | - | $60.77 M(+56.3%) |
| June 2001 | - | $38.89 M(+12.9%) |
| Mar 2001 | - | $34.45 M(-68.1%) |
| Dec 2000 | $190.72 M(+88.5%) | $108.02 M(+272.0%) |
| Sept 2000 | - | $29.04 M(+5.3%) |
| June 2000 | - | $27.58 M(+5.9%) |
| Mar 2000 | - | $26.05 M(-5.3%) |
| Dec 1999 | $101.20 M(+31.6%) | $27.50 M(+17.0%) |
| Sept 1999 | - | $23.50 M(-8.5%) |
| June 1999 | - | $25.69 M(+5.3%) |
| Mar 1999 | - | $24.40 M(+1.2%) |
| Dec 1998 | $76.90 M(+22.1%) | $24.10 M(+17.6%) |
| Sept 1998 | - | $20.50 M(+22.0%) |
| June 1998 | - | $16.80 M(+8.4%) |
| Mar 1998 | - | $15.50 M(-12.4%) |
| Dec 1997 | $63.00 M(+8.4%) | $17.70 M(-7.8%) |
| Sept 1997 | - | $19.20 M(+43.3%) |
| June 1997 | - | $13.40 M(+7.2%) |
| Mar 1997 | - | $12.50 M(-50.6%) |
| Dec 1996 | $58.10 M(+19.5%) | $25.30 M(+145.6%) |
| Sept 1996 | - | $10.30 M(-9.6%) |
| June 1996 | - | $11.40 M(+2.7%) |
| Mar 1996 | - | $11.10 M(+5.7%) |
| Dec 1995 | $48.60 M(+20.6%) | $10.50 M(+1.9%) |
| Sept 1995 | - | $10.30 M(-38.7%) |
| June 1995 | - | $16.80 M(+52.7%) |
| Mar 1995 | - | $11.00 M(-0.9%) |
| Dec 1994 | $40.30 M(+50.9%) | $11.10 M(+7.8%) |
| Sept 1994 | - | $10.30 M(+1.0%) |
| June 1994 | - | $10.20 M(+15.9%) |
| Mar 1994 | - | $8.80 M(-6.4%) |
| Dec 1993 | $26.70 M(+93.5%) | $9.40 M(+28.8%) |
| Sept 1993 | - | $7.30 M(+30.4%) |
| June 1993 | - | $5.60 M(+27.3%) |
| Mar 1993 | - | $4.40 M(+12.8%) |
| Dec 1992 | $13.80 M(+56.8%) | $3.90 M(+8.3%) |
| Sept 1992 | - | $3.60 M(+9.1%) |
| June 1992 | - | $3.30 M(+10.0%) |
| Mar 1992 | - | $3.00 M(+20.0%) |
| Dec 1991 | $8.80 M(+37.5%) | $2.50 M(+13.6%) |
| Sept 1991 | - | $2.20 M(+4.8%) |
| June 1991 | - | $2.10 M |
| Dec 1990 | $6.40 M | - |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual total expenses?
- What is the all time high annual total expenses for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual total expenses year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly total expenses?
- What is the all time high quarterly total expenses for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly total expenses year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual total expenses?
The current annual total expenses of VRTX is $5.56 B
What is the all time high annual total expenses for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual total expenses is $5.56 B
What is Vertex Pharmaceuticals Incorporated annual total expenses year-on-year change?
Over the past year, VRTX annual total expenses has changed by +$996.40 M (+21.83%)
What is Vertex Pharmaceuticals Incorporated quarterly total expenses?
The current quarterly total expenses of VRTX is $1.64 B
What is the all time high quarterly total expenses for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly total expenses is $1.71 B
What is Vertex Pharmaceuticals Incorporated quarterly total expenses year-on-year change?
Over the past year, VRTX quarterly total expenses has changed by +$247.80 M (+17.80%)